{"id":"add-on-sulphonylurea","safety":{"commonSideEffects":[{"rate":"5–20","effect":"Hypoglycemia"},{"rate":"2–3","effect":"Weight gain"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sulfonylureas bind to and close ATP-sensitive potassium channels on the surface of pancreatic beta cells. This closure depolarizes the cell membrane, triggering calcium influx and subsequent insulin exocytosis. When used as add-on therapy, they complement other antidiabetic agents to enhance overall glycemic control.","oneSentence":"Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, thereby lowering blood glucose in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:17.006Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus as add-on therapy"}]},"trialDetails":[{"nctId":"NCT07465926","phase":"","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2017-01-01","conditions":"Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease","enrollment":451036},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT07314684","phase":"PHASE4","title":"GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM","status":"RECRUITING","sponsor":"Federico II University","startDate":"2025-09-08","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":80},{"nctId":"NCT07241897","phase":"PHASE3","title":"DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-12-15","conditions":"Ischemic Stroke, Diabete Mellitus","enrollment":312},{"nctId":"NCT06716216","phase":"PHASE3","title":"A Study of BGM0504 in Participants with Type 2 Diabetes","status":"RECRUITING","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2024-11-29","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":537},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT02911792","phase":"PHASE4","title":"Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-12-20","conditions":"Diabetes Mellitus, Type 2","enrollment":72},{"nctId":"NCT03877406","phase":"PHASE4","title":"Effect of Empagliflozin on Body Composition and Ketones","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-08-01","conditions":"Diabetes Mellitus, Fat; Intolerance, Pancreas","enrollment":200},{"nctId":"NCT05688332","phase":"PHASE3","title":"Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients","status":"UNKNOWN","sponsor":"University of Zambia","startDate":"2023-08","conditions":"Diabetes Mellitus Type 2 Without Complication","enrollment":118},{"nctId":"NCT03871621","phase":"PHASE4","title":"Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2019-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT02919345","phase":"PHASE4","title":"Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease, Carotid Artery Diseases","enrollment":98},{"nctId":"NCT03076112","phase":"PHASE3","title":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2017-04-25","conditions":"Type 2 Diabetes Mellitus","enrollment":170},{"nctId":"NCT05102071","phase":"","title":"Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2021-11-01","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":""},{"nctId":"NCT03486964","phase":"","title":"Use of Incretins in Diabetic Patients","status":"COMPLETED","sponsor":"University of Pavia","startDate":"2018-03-27","conditions":"Diabetes Mellitus, Type 2","enrollment":2234},{"nctId":"NCT05386186","phase":"PHASE4","title":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes","enrollment":192},{"nctId":"NCT02941367","phase":"PHASE4","title":"Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-23","conditions":"Diabetes Mellitus, Type 2","enrollment":184},{"nctId":"NCT04146155","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus","enrollment":200},{"nctId":"NCT02686177","phase":"PHASE4","title":"Effect of GLP-1 on Angiogenesis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-18","conditions":"Type 2 Diabetes","enrollment":50},{"nctId":"NCT03066830","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-02-24","conditions":"Type 2 Diabetes Mellitus","enrollment":507},{"nctId":"NCT04013581","phase":"PHASE4","title":"Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2019-08-05","conditions":"Type 2 Diabetes Mellitus","enrollment":121},{"nctId":"NCT02653209","phase":"PHASE4","title":"TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-11-01","conditions":"Type 2 Diabetes","enrollment":525},{"nctId":"NCT03655535","phase":"PHASE2","title":"Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes","status":"COMPLETED","sponsor":"Boston Therapeutics","startDate":"2018-09-19","conditions":"Type2 Diabetes Mellitus","enrollment":66},{"nctId":"NCT02730377","phase":"PHASE4","title":"Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-03-28","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1991},{"nctId":"NCT01648582","phase":"PHASE3","title":"A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":774},{"nctId":"NCT02515526","phase":"NA","title":"Effect of Acute Ethanol Consumption on The Activity of Major Cytochrome P450 Enzymes, NAT2 and P-glycoprotein","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2015-06","conditions":"AOD Effects and Consequences","enrollment":16},{"nctId":"NCT02613897","phase":"NA","title":"ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 2","enrollment":56},{"nctId":"NCT03983551","phase":"PHASE4","title":"Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas","status":"COMPLETED","sponsor":"Changhua Christian Hospital","startDate":"2016-03-01","conditions":"Type 2 Diabetes Mellitus, Proteinuria","enrollment":101},{"nctId":"NCT02128932","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1089},{"nctId":"NCT02471404","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":939},{"nctId":"NCT02207374","phase":"PHASE3","title":"A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":601},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT01404676","phase":"PHASE4","title":"The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-06","conditions":"Type 2 Diabetes Mellitus","enrollment":34},{"nctId":"NCT02610088","phase":"PHASE4","title":"Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-11","conditions":"Diabetes","enrollment":32},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT02219750","phase":"PHASE4","title":"Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2013-08","conditions":"Diabetes","enrollment":181},{"nctId":"NCT02693392","phase":"NA","title":"Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2016-01-17","conditions":"Type-2 Diabetes Mellitus","enrollment":200},{"nctId":"NCT01177384","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-25","conditions":"Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT01618162","phase":"PHASE3","title":"The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-29","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":435},{"nctId":"NCT02786823","phase":"PHASE2, PHASE3","title":"Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2017-05-01","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT00086515","phase":"PHASE3","title":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-30","conditions":"Diabetes Mellitus, Type II","enrollment":701},{"nctId":"NCT03125694","phase":"PHASE3","title":"Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-02-01","conditions":"Uncontrolled Type 2 Diabetes Mellitus","enrollment":250},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":"Diabetes Mellitus, Type 2","enrollment":4447},{"nctId":"NCT00789191","phase":"PHASE3","title":"Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":222},{"nctId":"NCT00518882","phase":"PHASE3","title":"Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":467},{"nctId":"NCT00968812","phase":"PHASE3","title":"CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1452},{"nctId":"NCT01511172","phase":"PHASE2","title":"Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT02269098","phase":"NA","title":"The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2012-02","conditions":"Diabetes Mellitus, Type 2, Medication Adherence, HYPERGLYCEMIA","enrollment":101},{"nctId":"NCT01649466","phase":"PHASE4","title":"Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Type 2 Diabetes Mellitus","enrollment":162},{"nctId":"NCT00094770","phase":"PHASE3","title":"An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1172},{"nctId":"NCT00755287","phase":"PHASE3","title":"A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11","conditions":"Diabetes Mellitus Type 2","enrollment":1072},{"nctId":"NCT02282423","phase":"NA","title":"PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2014-05","conditions":"Diabetes, Obesity","enrollment":26},{"nctId":"NCT02420392","phase":"NA","title":"Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2015-02","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT00486187","phase":"NA","title":"Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study","status":"COMPLETED","sponsor":"Dr. Milan Gupta","startDate":"2006-04","conditions":"Type 2 Diabetes Mellitus","enrollment":103},{"nctId":"NCT01769378","phase":"PHASE3","title":"Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":300},{"nctId":"NCT02027753","phase":"PHASE4","title":"Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12","conditions":"Diabetes Mellitus, Type 2","enrollment":109},{"nctId":"NCT00700856","phase":"PHASE4","title":"Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial","status":"UNKNOWN","sponsor":"Italian Society of Diabetology","startDate":"2008-09","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":3371},{"nctId":"NCT00106704","phase":"PHASE3","title":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":441},{"nctId":"NCT00907881","phase":"","title":"The OBSTACLE Hypoglycemia Study (MK-0000-158)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":1069},{"nctId":"NCT02133118","phase":"","title":"Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin.","status":"COMPLETED","sponsor":"Medical Research Foundation, The Netherlands","startDate":"1998-01","conditions":"Type 2 Diabetes Mellitus","enrollment":16293},{"nctId":"NCT01159600","phase":"PHASE3","title":"Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-07","conditions":"Diabetes Mellitus, Type 2","enrollment":1504},{"nctId":"NCT01368081","phase":"PHASE3","title":"Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1162},{"nctId":"NCT01867502","phase":"PHASE4","title":"Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2, Hypoglycemic Agents, Diabetic Blood Glucose Monitoring","enrollment":20},{"nctId":"NCT01357252","phase":"PHASE3","title":"Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04","conditions":"Type 2 Diabetes Mellitus","enrollment":279},{"nctId":"NCT01204294","phase":"PHASE3","title":"Comprehensive Add on Study in Japan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-09","conditions":"Diabetes Mellitus, Type 2","enrollment":574},{"nctId":"NCT02015780","phase":"PHASE3","title":"Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease","enrollment":""},{"nctId":"NCT01195259","phase":"","title":"Malignancy Meta Analysis for BRL49653","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 2","enrollment":1},{"nctId":"NCT01020123","phase":"PHASE2","title":"Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type II Diabetes Mellitus","enrollment":530},{"nctId":"NCT01706211","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of BRL 49653C in Non-insulin Dependent Diabetes","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"1998-10","conditions":"Diabetes Mellitus Non Insulin Dependent Oral Agent Therapy","enrollment":77},{"nctId":"NCT00975065","phase":"PHASE4","title":"Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":266},{"nctId":"NCT01420692","phase":"NA","title":"The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Ankara University","startDate":"2010-06","conditions":"Type 2 Diabetes Mellitus","enrollment":64},{"nctId":"NCT00562172","phase":"PHASE4","title":"Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Type 2 Diabetes Mellitus","enrollment":75},{"nctId":"NCT01624116","phase":"NA","title":"Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes","status":"COMPLETED","sponsor":"Services Hospital, Lahore","startDate":"2011-08","conditions":"Diabetes, Type 2","enrollment":161},{"nctId":"NCT00575588","phase":"PHASE3","title":"52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-12","conditions":"Type 2 Diabetes","enrollment":891},{"nctId":"NCT01336751","phase":"PHASE3","title":"Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-07","conditions":"Diabetes Mellitus, Type 2","enrollment":212},{"nctId":"NCT00358124","phase":"PHASE4","title":"Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-01","conditions":"Type 2 Diabetes Mellitus","enrollment":220},{"nctId":"NCT00046462","phase":"PHASE3","title":"Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-11","conditions":"Diabetes Mellitus","enrollment":240},{"nctId":"NCT00384215","phase":"PHASE4","title":"Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-12","conditions":"Diabetes Mellitus, Type 2","enrollment":352},{"nctId":"NCT00808860","phase":"PHASE1, PHASE2","title":"Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Hanoi Medical University","startDate":"2008-02","conditions":"Type 2 Diabetes","enrollment":25},{"nctId":"NCT00417729","phase":"PHASE4","title":"Effects of Acarbose Versus Glibenclamide on MAGE and Oxidative Stress in Patients With Type 2 DM","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2007-01","conditions":"Diabetes Mellitus","enrollment":51},{"nctId":"NCT00150410","phase":"PHASE3","title":"Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":"Diabetes Mellitus","enrollment":626},{"nctId":"NCT00776607","phase":"NA","title":"Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA)","status":"UNKNOWN","sponsor":"Abertawe Bro Morgannwg University NHS Trust","startDate":"2007-04","conditions":"Latent Autoimmune Diabetes in Adults LADA","enrollment":200},{"nctId":"NCT00251940","phase":"PHASE3","title":"GALLANT 7 Tesaglitazar Add-on to Sulphonylurea","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2004-07","conditions":"Type 2 Diabetes","enrollment":555},{"nctId":"NCT00325117","phase":"PHASE3","title":"To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-04","conditions":"Diabetes Mellitus, Type 2","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":68,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"add-on sulphonylurea","genericName":"add-on sulphonylurea","companyName":"Italian Society of Diabetology","companyId":"italian-society-of-diabetology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, thereby lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus as add-on therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}